Atherogenic dyslipidemia;Dislipemia aterogénica

Clinica e Investigacion en Arteriosclerosis

Volumn 24, Issue SUPPL. 1, 2012, Pages 3-7

  González Santos, Pedro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Dense LDL; Hypertriglyceridemia; Hypoalphalipoproteinemia; Residual risk; Small

Indexed keywords

APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIPOGENESIS; METABOLIC SYNDROME X; OXIDATION; PATHOGENESIS; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875525733     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/S0214-9168(12)70006-2     Document Type: Article

References (18)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
2. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
3. González Santos P, González Alegre T. Mecanismos aterogénicos que hacen que la diabetes mellitus sea una enfermedad de alto riesgo cardiovascular. En: Fabiani F, Torres J, editores. La enfermedad cardiovascular: un reto para todos. Madrid: EGRAF; 2001. p. 113-39.
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. HelsinKi Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
5. Arca M, Montali A, Valiante S, Campagna F, Pigna G, Paoletti V, et al. Usefulness of atherogenic dyslipidemia from predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol. 2007;100:1511-6.
6. Carey VJ, Bdihop L, Laranjo N, Harshfield BB, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low highdensity lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757-63.
7. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, et al. Coronary heart disease in patients with low LDLcholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424-8.
8. The Emerging Risk Factors Collaboration. Major lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009;302:1993-2000.
9. Muntner P, Lee F, Astor BC. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: The Atherosclerosis Risk in Communities Study. Amer J Med Sci. 2011;341:173-80.
10. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-10.
11. Grover SA, Kaouache M, Joseph L, Barter P, Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other lipid levels. Arch Intern Med. 2009;169:1775-80.
12. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis for the JUPITER trial. Lancet. 2010;376:333-9.
13. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy fot atherosclerosis regresión and prevention of cardiovascular disease events. J Am Coll Cardiol. 2012;59:2058-64.
14. Brewer HB Jr. The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab. 2011;96:1246-57.
15. Khera AV, Cuchel M, De la LLera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.
16. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of HDL on eNOS activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-708.
17. Schwartz EA, Reaven PD. Lipolysys of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta. 2012;1821:858-66.
18. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-9.